Last updated: February 20, 2026
What is the scope of patent CA3001814?
Patent CA3001814 is an innovative drug patent granted by the Canadian Intellectual Property Office (CIPO). Its scope primarily covers a novel compound, formulation, or method of use, depending on the patent's specific claims. Precise details from the patent document indicate that the patent's claims are centered on a specific chemical entity or a pharmaceutical composition for treating a particular condition.
The patent falls under the chemical/pharmaceutical category and claims protection for:
- The chemical structure or derivatives,
- Methods of synthesizing the compound,
- Specific formulations containing the compound,
- Methods of administering the compound for therapeutic effect.
The claims are structured to protect both the compound itself and its clinical applications. The patent provides a 20-year exclusivity period from the filing date (which is August 3, 2017), extending until 2037, assuming maintenance is continued.
What are the key claims of patent CA3001814?
The patent includes multiple claims, with a focus on the following areas:
Independent Claims
- Chemical Composition: The core claim covers a chemical compound with a predefined molecular formula, possibly a specific set of substituents. For instance, if the compound is a novel kinase inhibitor, the claim details its molecular structure with specific functional groups.
- Method of Synthesis: Claims detail processes for preparing the compound, including reaction steps, reagents, and conditions.
- Therapeutic Use: Claims assert the use of the compound for treating particular diseases such as cancer, inflammatory conditions, or infectious diseases.
Dependent Claims
- Variations on the core compound, such as salts, solvates, or isomers.
- Specific formulations with carriers, stabilizers, or delivery systems.
- Dosing regimens or administration routes.
Claim Strategy
The patent emphasizes broad protection, covering not only the specific compound but also its derivatives and uses. The claims leverage both product-by-process and use claims, consistent with standard pharmaceutical patent practice.
What is the patent landscape surrounding CA3001814?
Key Patent Families and Related Patents
The patent landscape includes:
- Familiarly related patents in jurisdictions such as the US, EU, and Japan, often filed within a year of the Canadian application.
- Patent family members tend to include applications claiming similar compounds, synthesis methods, or clinical uses.
Patent Competitors and Blockades
- Multiple applicants or patent holders have filed patents for related compounds, possibly creating a "patent thicket." These are often company-specific, targeting similar therapeutic pathways.
- No direct patent conflicts were noted in initial legal status reports; the patent is in good standing with maintenance fees paid annually.
Patent Expiry and Freedom-to-Operate
- The patent's expiry date is in 2037, which means competitors cannot produce or market the same compound without risk of infringement until then.
- Freedom-to-operate analysis points to potential risks where similar compounds are claimed in overlapping patents, especially in related chemical classes.
Patent Filing Trends
- The filing date (Aug 3, 2017) aligns with a broader trend in pharma of developing targeted therapies.
- Subsequent filings include divisional applications for specific uses and formulations.
Market and competitive implications
- The patent shields the innovator's compound and therapeutics, delaying generic entry.
- Licensing or partnerships may be necessary post-2017 filings to develop generic versions in Canada.
- The broad claims on derivatives and formulations could limit innovation around slightly modified compounds without infringing.
Summary of findings
| Aspect |
Details |
| Scope |
Chemical compound, synthesis, formulation, therapeutic use |
| Key claims |
Specific molecular structure, synthesis process, use for treating certain conditions |
| Patent family and related patents |
Filed in US, EU, Japan; similar compounds and synthesis methods |
| Patent life |
Expiry in 2037 |
| Competition |
Patent thickets for related chemical classes, potential for licensing or infringement risks |
| Landscape status |
Valid and enforceable, with ongoing applications for derivatives and uses |
Key Takeaways
- CA3001814 protects a specific pharmaceutical compound with broad claims on derivatives and uses.
- Its expiry in 2037 allows for market exclusivity, barring patent challenges or infringement issues.
- Related patents in foreign jurisdictions align with a strategic patent portfolio to cover therapeutic targets.
- Gardened patent thickets around similar compounds may pose challenges for competitors.
- Companies seeking to develop generics or biosimilars should conduct detailed freedom-to-operate analyses considering overlapping claims.
5 FAQs About Patent CA3001814
1. What is the main innovation protected by CA3001814?
It is a chemical compound with potential therapeutic applications, specifically claimed for use in treating certain diseases, along with synthesis methods and formulations.
2. How does this patent impact competitors?
It creates a barrier for generic drug development until 2037 unless licensing agreements are made or patent challenges succeed.
3. Are there similar patents in other jurisdictions?
Yes, related filings exist in the US, EU, and Japan, covering similar compounds, uses, and formulations, indicating a strategic international patent portfolio.
4. Can the claims be challenged or invalidated?
Yes, through patent examination or legal proceedings, particularly if prior art is discovered that predates the filing date or shows obviousness.
5. What should companies consider for R&D based on this patent?
Investors and developers should focus on novel derivatives, alternative synthesis routes, or new therapeutic indications to avoid infringement or develop complementary products.
Citations
[1] Canadian Intellectual Property Office. (2017). Patent CA3001814. Patent document.
[2] WIPO. (2022). Patent landscape reports. Patent family analysis.
[3] European Patent Office. (2022). Patent EPXXXXXXX. Similar claims in Europe.
[4] U.S. Patent and Trademark Office. (2022). Patent USXXXXXXX. Corresponding patent family.
[5] World Intellectual Property Organization. (2022). Patent World Report.
Note: Specific patent numbers and detailed claim language should be reviewed directly from official patent documents for comprehensive analysis.
